Skip to contentV
Vitaspring Biomedical Co. Ltd.
V
VSBCVitaspring Biomedical Co. Ltd. Q2 2025 · 10-Q
Revenue$0.00$0.00— vs Q2 2024 Net Income-$218.66K-$218.66KN/M vs Q2 2024 EPS Diluted$0.00$0.00— vs Q2 2024 Operating Income-$218,662N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Vitaspring Biomedical Co. Ltd. · CIK 1697884 · Engraved from SEC EDGAR
derived
ended Jul 31, 2024 · filed Apr 22, 2026 · 630 d after period end